Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board

Health and medicine

Home » Health and medicine

Beam Therapeutics Announces Closing of Initial Public Offering

February 11, 2020 07:41 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing...

DNA computer

Synthetic biology is shaking up these 5 industries–Some of them might surprise you

Precigen Completes Series Of Transactions To Solidify Healthcare Focus

– Company on Track to Advance Next-Generation Gene & Cell Therapies – – Company Name Changes to Precigen from Intrexon and Ticker Symbol to Nasdaq: PGEN – GERMANTOWN, Md., Feb. 3, 2020...

Mammoth Biosciences

Mammoth Biosciences Raises $45 Million to Build Next Generation CRISPR Products For Therapeutics and Diagnostics

Mammoth Biosciences

The CRISPR Platform for Next-Generation Therapeutics and Diagnostics

Synlogic Appoints Dr. Michael Burgess to its Board of Directors

AbCellera Is Mobilizing a Response to the Novel Coronavirus Outbreak as Part of Its DARPA P3 Program

Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

CORRECTING and REPLACING IDT Offers Preferred Pricing and Early Access to Complete Portfolio of Coronavirus Research Tools

Beam Therapeutics Promotes Giuseppe Ciaramella, Ph.D., to President and Chief Scientific Officer

Berkeley Lights Launches Next Generation B Cell Workflow to Accelerate Therapeutic Antibody Discovery

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

Lygos Acquires Librede to Accelerate Cannabinoid Production for Consumer, Nutraceutical and Pharmaceutical Products

Twist Bioscience Announces Strategic Collaboration With Schrödinger for Drug Discovery

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968